The Promising Effect of Colchicine on Random-Pattern Skin Flap Survival in Rats: Glutamate Pathway

Tabary, Mohammadreza; Aryannejad, Armin; Noroozi, Nafise; Iranshahi, Setare; Jafari, Razieh Mohammad; Mashinchi, Baharnaz; Tavangar, Seyed Mohammad; Araghi, Farnaz; Dehpour, Ahmad Reza

doi:10.1016/j.jss.2022.01.026

Cited by 3 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimental studies have shown that the use of colchicine in random pattern flaps significantly reduces the area of necrosis in the flap [ 10 ]. In this study, it was reported that interleukin-6 and tumor necrosis factor-α levels decreased and N-methyl-D-aspartate (NMDA) receptors increased in flaps in the colchicine group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Breast Reduction in Behçet's Disease: A Case Report

Ors

2023

Cureus

View full text Add to dashboard Cite

Behçet's disease (BD) is an inflammatory systemic vasculitis manifested by uveitis and oral and genital aphthae. There have been no reported cases in the literature about reduction mammoplasty or large flap surgeries in BD. A 55-year-old female with a 16-year history of BD was presented to our clinic for reduction mammoplasty. The patient was taking colchicine and had records of uveitis and oral and genital aphthae. Colchicine treatment was stopped one week before surgery and restarted one week later. Reduction mammoplasty was performed with the inferior pedicle technique. On the first day after surgery, mild hyperemia and induration were observed around the incision line, worsening over the next 48-72 hours with the appearance of serous discharge at the vertical suture line and inverted T incision. Minimal wound dehiscence developed on the seventh day, and a small superficial necrosis developed at the lower part of the vertical suture on the 15th day. Between days 30 and 45, the necrotic tissue sloughed off, and the wound closed with epithelialization. In conclusion, patients with BD may experience prolonged inflammation, small skin necroses around the incision line, and delayed wound healing post surgery, although acceptable scar maturation can eventually be achieved.

show abstract

Section: Discussionmentioning

confidence: 99%

“…If possible, low-dose use would be appropriate after surgery. The number of studies on colchicine is limited [ 6 , 10 ]. We had to start the colchicine again as the inflammation increased too much after operation.…”

Section: Discussionmentioning

confidence: 99%

Breast Reduction in Behçet's Disease: A Case Report

Ors

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Colchicine, a decades-old anti-inflammatory drug used to treat gout, has similarly shown promise in mitigating inflammation and IRI-mediated necrosis through the glutamate pathway, ultimately resulting in enhanced skin flap survival [ 67 ]. The application of colchicine to ischemia/reperfusion injured rats reduced proinflammatory cytokines IL-6 and TNF-α and mildly increased glutamate and N -methyl- D -aspartate subunit 2A receptor expression, a glutamate receptor found on nerve cells and keratinocytes of the skin with known cytoprotective capabilities [ 67 ]. Furthermore, colchicine inhibited microtubule polymerization, which affects neutrophil adhesion, mobilization, and recruitment.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, colchicine inhibited microtubule polymerization, which affects neutrophil adhesion, mobilization, and recruitment. Inflammation was attenuated through increased induction of the M2 macrophage phenotype, which is known for dampening of the immune response [ 67 ].…”

Section: Introductionmentioning

confidence: 99%

Pharmacological and cell-based treatments to increase local skin flap viability in animal models

Berry,

Le,

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Local skin flaps are frequently employed for wound closure to address surgical, traumatic, congenital, or oncologic defects. (1) Despite their clinical utility, skin flaps may fail due to inadequate perfusion, ischemia/reperfusion injury (IRI), excessive cell death, and associated inflammatory response. (2) All of these factors contribute to skin flap necrosis in 10–15% of cases and represent a significant surgical challenge. (3, 4) Once flap necrosis occurs, it may require additional surgeries to remove the entire flap or repair the damage and secondary treatments for infection and disfiguration, which can be costly and painful. (5) In addition to employing appropriate surgical techniques and identifying healthy, well-vascularized tissue to mitigate the occurrence of these complications, there is growing interest in exploring cell-based and pharmacologic augmentation options. (6) These agents typically focus on preventing thrombosis and increasing vasodilation and angiogenesis while reducing inflammation and oxidative stress. Agents that modulate cell death pathways such as apoptosis and autophagy have also been investigated. (7) Implementation of drugs and cell lines with potentially beneficial properties have been proposed through various delivery techniques including systemic treatment, direct wound bed or flap injection, and topical application. This review summarizes pharmacologic- and cell-based interventions to augment skin flap viability in animal models, and discusses both translatability challenges facing these therapies and future directions in the field of skin flap augmentation.

show abstract